Glaxo's antiulcerant Zantac (ranitidine) in combination with amoxycillin and metronidazole has been approved in the UK as a treatment for duodenal ulcers associated with Helicobacter pylori infection. The recommended dosage regimen is Zantac 300mg at night plus amoxycillin (750mg three times daily) and metronidazole (500mg three times daily). Glaxo states that the cost per eradication for this therapy will be L37.43 ($59.13) compared to L72.15 for omeprazole dual therapy, the only other eradication therapy approved in the UK.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze